Alnylam’s 20-Year Journey of Discovery
Twenty years ago, a group of scientists intent on developing a new class of medicine using RNAi technology came together and formed Alnylam Pharmaceuticals, a name symbolizing their passion for discovery. The bright center star of Orion's belt, Alnilam, has long been used as a celestial navigator, guiding explorers in their mission to discover the world. Like many explorers, the ...
New CRISPR Technique May Be the Solution to Replacing Entire Genes
Ever since it was discovered that CRISPR could be used for genome editing, scientists across the world have been working on creating safe, effective ways to use this incredible tool to cure many different human diseases. From the first CRISPR-Cas system that works as genetic scissors to base editing and then Prime editing, incredible innovation has been on full ...
Using CRISPR to Personalize Cancer Immunotherapy Treatment
In 2020, there were an estimated 18.1 million cases of cancer worldwide (excluding non-melanoma skin cancer). Breast, lung, and colorectal cancer were the most common and together contributed to 35.4% of these cases. In the same year, 9.5 million cancer-related deaths were reported. According to the NIH, by 2040, it is expected that there will be 29.5 million new cases ...
Will N-of-1 Drugs Play a Role in the Future of Medicine?
Throughout the millennia, anyone who had anything beyond a simple illness could only do their best to ease the pain and petition whatever deities their culture believed in. Then, in the past few centuries, medicine and science have advanced to the point that many illnesses and diseases can be successfully treated. Unfortunately, rare diseases have not been given the ...
Centyrins Effectively and Safely Deliver siRNAs to Multiple Muscle Tissues
In 2018, Susan Dillon and Karyn O'Neil knew they had created something special that could change the treatment of genetic diseases. Now, their company’s drug that uses their proprietary technology has been granted orphan drug status by the U.S Food and Drug Administration (FDA). The drug, ABX1100, is designed to treat the debilitating genetic condition called Pompe disease. What ...
Reflections following the 20th annual meeting on oligonucleotide therapeutics
Footnote from title: modified slightly from “A brief history of oligonucleotide therapeutics” in the Timmerman Report, copyright 2022, and reprinted with permission. A Brief History of Oligonucleotide Therapeutics About 50 years ago, several scientists independently conceived of the idea of blocking gene expression with synthetic DNA or RNA “antisense” oligonucleotides (ASO) designed to bind specifically to complementary “sense” mRNA ...
Alnylam’s 20-Year Journey of Discovery
Twenty years ago, a group of scientists intent on developing a new class of medicine using ...
New CRISPR Technique May Be the Solution to Replacing Entire Genes
Ever since it was discovered that CRISPR could be used for genome editing, scientists across ...
Using CRISPR to Personalize Cancer Immunotherapy Treatment
In 2020, there were an estimated 18.1 million cases of cancer worldwide (excluding non-melanoma skin cancer). ...
Will N-of-1 Drugs Play a Role in the Future of Medicine?
Throughout the millennia, anyone who had anything beyond a simple illness could only do their ...
Centyrins Effectively and Safely Deliver siRNAs to Multiple Muscle Tissues
In 2018, Susan Dillon and Karyn O'Neil knew they had created something special that could ...
Reflections following the 20th annual meeting on oligonucleotide therapeutics
Footnote from title: modified slightly from “A brief history of oligonucleotide therapeutics” in the Timmerman ...